1/20/2010

Annual Summary of Stock Exchange Releases published in 2009

Orion Corporation - Stock Exchange Release

 

 

ORION CORPORATION: Annual Summary of Stock Exchange Releases published in 2009

ORION CORPORATION      STOCK EXCHANGE RELEASE  20 JAN 2010  AT 12.30  EET              

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases published by the company in 2009. The releases are available on the internet website of Orion Corporation, at http://www.orion.fi/sereleases.

Orion points out that part of the information in the releases can have become out-dated.

Stock Exchange Releases in 2009

Jan 7th 2009

Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland

Jan 15th 2009

Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®

Jan 16th 2009

Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008

Jan 19th 2009

Orion publishes 2008 Financial Statement release on 6 Feb 2009

Jan 28th 2009

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation

Feb 6th 2009

Orion Group Financial Review of 2008

Feb 6th 2009

Matters to be handled at the AGM of Orion Corporation on 23 March 2009

Feb 24th 2009

Orion: Primary objective of STRIDE-PD study was not achieved

Mar 4th 2009

Orion Group Annual Report 2008 published

Mar 5th 2009

Orion Corporation: Transfer of 44,806 own B-shares

Mar 6th 2009

Orion withdraws EU application for extending the indication of Stalevo®

Mar 23rd 2009

Orion Corporation: Decisions by the AGM on 23 March 2009

Mar 23rd 2009

Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees

Apr 14th 2009

Amendments to Orion's Articles of Association entered in the Trade Register

Apr 20th 2009

Orion invites to a Q1 news conference on Monday 27 April 2009

Apr 27th 2009

Orion Group Interim Report 1-3/2009

Apr 29th 2009

Orion and Wockhardt settle patent dispute

May 6 2009

Orion reacquires rights for i.v. levosimendan (Simdax®)

Jun 10th 2009

Orion invites analysts and media to Q2 news conference on Friday 7 August 2009

Jul 31st 2009

Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States

Aug 7th 2009

Orion Group Interim Report January-June 2009

Aug 7th 2009

Orion: Correction to English version of Interim Report 1-6/2009

Sep 4th 2009

Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex®

Sep 21st 2009

Composition of the Nomination Committee of Orion Corporation

Oct 6th 2009

Orion invites analysts and media to Q3 news conference on Monday 26 October 2009

Oct 21st 2009

Orion withdraws US application for extending the indication of Stalevo®

Oct 26th 2009

Orion Corporation's publication schedules for financial reporting in 2010

Oct 26th 2009

Orion Group Interim Report January-September 2009

Nov 27th 2009

100,000 Orion A-shares converted into B-shares

Dec 4th 2009

Orion clarifies information emanating from Capital Markets Day

Orion Corporation

Timo Lappalainen                 Olli Huotari

President and CEO              SVP, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

The Group's net sales in 2008 amounted to EUR 711 million. The Company invested EUR 90 million in research and development. At the end of 2008, the Group had a total of 3,300 employees, of whom 2,700 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.